688222.SHG HitGen Inc. A

Healthcare Biotechnology Shanghai Stock Exchange
35.61 CNY
Close of Nov 4, 2026
21.35 47.58
Market cap
CNY 14.3B
P/E
86.9x
P/B
8.47x
ROE
11.7%
Dividend yield
0.24%
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is 688222.SHG undervalued?

Graham number

The Graham number of HitGen Inc. A cannot be estimated reliably (the estimate is too far from the market price).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

HitGen Inc. A fundamental analysis

No fundamental analysis for HitGen Inc. A yet.

HitGen Inc. A stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About HitGen Inc. A

HitGen Inc. operates as a drug discovery research platform for small molecules and nucleic acid drugs in China and internationally. Its technology platform includes DNA-encoded library technology; fragment-based drug discovery and structure-based drug design technologies; virtual screening; emerging technology platforms for synthetic therapeutic oligonucleotide technology; and targeted protein degradation technology. The company's product pipeline also includes HG146, which …

Full company profile